Radioligand Binding
Receptor Occupancy
Receptor Autoradiography
Cellular Uptake & Release
SPR (Biacore)
Gifford Bioscience Limited is a preclinical contract research organization (CRO) providing specialist services in radioligand binding assays, receptor occupancy studies, autoradiography and SPR.
At Gifford Bioscience, we employ “gold standard” radiometric methods, for maximum sensitivity and robustness, together with label-free, kinetic affinity techniques. We use cell membranes, live cells, human tissue and animal tissue.
Determination of receptor affinities and binding parameters for test compounds in a tissue homogenate or cell preparation.
Measurement of the degree to which a test compound engages its target receptor in live cells, tissues or in an animal.
Measurement of a compounds transport into cells or efflux from cells. Determination of a compound’s potency and efficacy.
Kinetic, label-fee measurement of a drug’s affinity for its receptor using Surface Plasmon Resonance (SPR).
“SPR Evaluation of Potential Anti-COVID-19 Therapies” poster presentation at ELRIG Drug Discovery Digital 2020
ELRIG Drug Discovery Digital 2020 is starting this week, and Dr Clare Box and Dr Kevin Thompson are going to be there, virtually, to present their research evaluating novel COVID-19 therapies through the use of SPR. ELRIG Drug Discovery DigitalfacebooktwitterCopyright © 2008 - 2020 Gifford Bioscience LimitedPrivacy Policy
Small Molecules, Binding to AT2 Site on ACE2, Unlikely to Prevent COVID-19 Spike Protein Binding
Angiotensin II and SARS-CoV-2 ‘spike’ protein bind to independent sites on angiotensin converting enzyme 2. We used the Biacore Surface Plasmon Resonance (SPR) technique to show that the peptide angiotensin II (AT2, that is normally truncated by the ACE2 receptor) and COVID-19 / SARS-CoV-2 spike protein bind to different sites on the enzyme. When pre-mixed, both AT2 and spike protein are still...
